Compare Mesoblast Limited (MESO) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Nomura Holdings Inc — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Nomura Holdings Inc trades at $9.59 (market cap $27.55B). The key difference: Nomura Holdings Inc is far larger — about 15.7× Mesoblast Limited's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Nomura Holdings Inc for 55 Days on average.
| MESO | NMR | |
|---|---|---|
Market Cap | $1.75B | $27.55B |
Volume | 239,027 | 782,470 |
Sector | Health | Financials |
52-Week High | $20.96 | $10.86 |
52-Week Low | $13.19 | $6.73 |
Typical Hold Time | 15 Days | 55 Days |
Enterprise Value | $1.83B | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Nomura Holdings (NMR) trades at $9.54, up 0.1% on the day, with a bearish technical signal but strong fundamental metrics including a P/E of 11.33 and net income margin of 20.4%. Recent earnings show a mix of beats and misses, while cash flow trends indicate significant financing activity. The stock is near its support level of $9, with RSI indicators suggesting potential oversold conditions. Zacks Research highlighted NMR as a strong buy for momentum and value in September 2026, citing recent price strength.
The outlook for NMR is cautiously optimistic, supported by solid profitability and valuation, but tempered by bearish technicals and inconsistent earnings performance. Key risks include high debt levels and macroeconomic sensitivity, while analyst sentiment leans hold. Upside potential exists if earnings stabilize and technical support holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
